Ac4-5SGlcNAc

製品番号: HY-149552: Data Sheet 取扱説明書
FAQs
Technical Support

Ac4-5SGlcNAc is an O-GlcNAc transferase (OGT) inhibitor. Ac4-5SGlcNAc converts intracellularly to UDP-5SGlcNAc, which competes with native UDP-GlcNAc (HY-148596) to block OGT catalytic activity, reduces cellular UDP-GlcNAc pools, and limits global protein O-GlcNAcylation. Ac4-5SGlcNAc reduces OGA levels via feedback, alters lectin signal intensities and glycan-related band masses. Ac4-5SGlcNAc can be used for the research of breast cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Ac4-5SGlcNAc 構造式

CAS 番号 : 67561-97-1

容量		在庫状況
MOQ		Minimum order quantity
50 mg		お問い合わせ
100 mg		お問い合わせ
250 mg		お問い合わせ
Other size		お問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

おすすめ

•関連小分子:

•関連タンパク質:

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

IC₅₀ & Target

Glycosyltransferase (OGT)^[1]

体外実験

Ac4-5SGlcNAc (50 μM; 24 h-5 days) potently reduces global O-GlcNAcylation in undifferentiated hESCs, downregulates OGA expression without altering hESC pluripotency or cell viability^[1].
Ac4-5SGlcNAc (50 μM; daily from day -2 to day 11 of neural differentiation) reduces global O-GlcNAcylation and cellular UDP-GlcNAc levels in differentiating hESCs, induces compensatory changes in OGT and OGA expression, and does not disrupt core pluripotency or neural progenitor marker expression^[1].
Ac4-5SGlcNAc (10-50 μM; daily from day -2 to day 11 of neural differentiation, 48 h prior to neural induction initiation) accelerates neuronal differentiation of H1, H7, and H9 hESCs, inducing premature expression of TUJ1 and MAP2, increasing neurite extension, and increasing the percentage of cells co-expressing these neuronal markers^[1].
Ac4-5SGlcNAc (50 μM; daily from day -2 to day 11 of neural differentiation) upregulates neuronal differentiation and forebrain development-related genes in differentiating H1 hESCs, driving transcriptomic changes consistent with accelerated neuronal commitment^[1].
Ac4-5SGlcNAc (50 μM; daily from day -2 to day 4 of neural differentiation) causes minor, transient changes to cell surface glycosylation in hESCs, with no detectable differences once neural induction is underway^[1].
Ac4-5SGlcNAc (50 μM; 2-24 h) inhibits global O-GlcNAcylation in CHO cells in vitro in a dose-dependent manner, with a maximal effect at 50 μM over 24 h and observable reduction starting at 4 h^[2].
Ac4-5SGlcNAc (50 μM; 24 h) modulates established OGT inhibition biomarkers in CHO cells, including a Nup62 mass shift, sOGT accumulation, and reduced OGA levels^[2].
Ac4-5SGlcNAc (50 μM; 24 h) inhibits global O-GlcNAcylation in CHO, HEK-293, HeLa, and D283-Med cells^[2].
Ac4-5SGlcNAc (50 μM; 24 h) alters specific cell surface glycan structures in CHO cells, as detected by reduced binding of lectins PHA-E, Jacalin, and LCA, while not grossly perturbing glycans recognized by several other tested lectins^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	undifferentiated human embryonic stem cells (hESCs)
Concentration:	50 μM
Incubation Time:	24 h; 5 days
Result:	Abrogated the majority of detectable protein O-GlcNAcylation after 24 h treatment. Caused a time-dependent decrease in O-GlcNAc levels for up to 3 days, after which levels started to increase following 5 days treatment. Decreased OGA protein expression over the 5-day period. Left OCT4 expression (a pluripotency marker) unaffected. Caused no changes in cell morphology or proliferation.

Western Blot Analysis^[1]

Cell Line:	hESCs undergoing neural differentiation
Concentration:	50 μM
Incubation Time:	daily from day -2 to day 11 of neural differentiation
Result:	Maintained consistently lower global O-GlcNAcylation levels than DMSO-treated controls while preserving the oscillation pattern characteristic of neural differentiation. Decreased OGA protein expression and increased OGT protein expression (compensatory changes). Left OCT4 and PAX6 expression unchanged relative to controls. Reduced UDP-GlcNAc levels significantly across all days of differentiation compared to DMSO-treated cells.

Immunofluorescence^[1]

Cell Line:	H1, H7, H9 hESCs undergoing neural differentiation
Concentration:	10 μM; 50 μM
Incubation Time:	daily from day -2 to day 11 of neural differentiation
Result:	Accelerated TUJ1 expression compared to controls after 50 μM treatment for 48 h before neural induction. Caused premature TUJ1 expression as early as day 8 and greater neurite extension via immunofluorescence when 50 μM was added daily from day -2 to day 11. Enabled detection of TUJ1 and MAP2 co-expression in H1, H7, and H9 hESC lines by day 11. Caused a 10-fold difference in TUJ1/MAP2 co-expression between treated and DMSO-treated cells by day 6; by day 11, 3% of treated cells co-expressed both markers, compared to 1% of control cells. Induced similar accelerated neuronal marker expression with 10 μM treatment.

Western Blot Analysis^[2]

Cell Line:	Chinese hamster ovary (CHO) cells
Concentration:	50 μM
Incubation Time:	24 h
Result:	Caused Nup62 to shift to a lower molecular weight, consistent with loss of O-GlcNAc residues. Resulted in accumulation of the short isoform of OGT (sOGT) while full-length ncOGT levels remained unchanged. Decreased levels of OGA (O-GlcNAcase).

Western Blot Analysis^[2]

Cell Line:	Chinese hamster ovary (CHO) cells, HEK-293 cells, HeLa cells, D283-Med cells
Concentration:	50 μM
Incubation Time:	24 h
Result:	Reduced global O-GlcNAc levels in all four tested mammalian cell lines.

分子量

405.42

分子式

C₁₆H₂₃NO₉S

CAS 番号

67561-97-1

SMILES

CC(O[C@H]1[C@@H]([C@H](S[C@@H]([C@@H]1NC(C)=O)OC(C)=O)COC(C)=O)OC(C)=O)=O

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

取扱説明書 (2659 KB)

参考文献

[1]. Andres LM, et al. Chemical Modulation of Protein O-GlcNAcylation via OGT Inhibition Promotes Human Neural Cell Differentiation. ACS Chem Biol. 2017;12(8):2030-2039. [Content Brief]

[2]. Vocadlo DJ, et al. Methods and compounds for inhibiting glycosyltransferases. United Kindom, WO2011137528. 2011-11-10.

[3]. Barkovskaya A, et al. Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells. Sci Rep. 2020;10(1):16992. Published 2020 Oct 12. [Content Brief]

Ac4-5SGlcNAc Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ac4-5SGlcNAc67561-97-1OGTO-linked N-acetylglucosaminyltransferaseO-GlcNAc transferasehESCsCHO cellsUDP-5SGlcNAcO-GlcNAcasebreast cancer cellUDP-GlcNAchuman embryonic stem cellOGAInhibitorinhibitorinhibit

最近チェックした製品:

製品名

カスタマ需要量 *

お名前 *

タイトル

メールアドレス *

電話番号 *

デパートメント

組纖名 *

市区町村

都道府県

国或いは地域 *

必ず会社名を記載ください。個人への返信は行いません。

備考

製品名

Lot #